Show simple item record

dc.contributor.authorRajabally, Yusuf A
dc.contributor.authorAfzal, Saadia
dc.contributor.authorGhasemi, Majid
dc.date.accessioned2024-08-28T12:25:22Z
dc.date.available2024-08-28T12:25:22Z
dc.date.issued2021-04-20
dc.identifier.citationRajabally YA, Afzal S, Ghasemi M. Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021 Jul;64(1):37-42. doi: 10.1002/mus.27250. Epub 2021 Apr 20en_US
dc.identifier.issn0148-639X
dc.identifier.eissn1097-4598
dc.identifier.doi10.1002/mus.27250
dc.identifier.pmid33835480
dc.identifier.urihttp://hdl.handle.net/20.500.14200/5533
dc.description.abstractIntroduction/aim: The use of outcome measures is recommended for chronic inflammatory demyelinating polyneuropathy (CIDP). Implications of minimal important differences (MID) to ascertain responder status are unknown. The reliability of patient-reported treatment-response in relation to clinically relevant change is also unknown. Methods: We retrospectively studied 72 subjects with "definite" or "probable" CIDP evaluated at pre-specified time-intervals pre- and post-treatment. We derived MID and the minimum detectable change with 95% confidence intervals (MDC95 ) for four scales. Scale sensitivities were determined with applicable MID-defined cutoffs (aMIDc), to detect subjects with self-identifying treatment response through a single question. Results: The use of MID was not valid for the Medical Research Council Sum Score, as MDC95 > MID. The aMIDc for the Overall Neuropathy Limitation Score (ONLS) was 1 (sensitivity: 84.7%). The aMIDc for the centile Inflammatory Rasch-built Overall Disability Scale (cI-RODS) was 8 (sensitivity: 62.3%). The aMIDc for grip strength was 4 kg (sensitivity: 79.1%). MID-defined amelioration of any one scale among ONLS, cI-RODS, or grip strength, significantly improved sensitivity to detect treatment-responders compared with the ONLS alone (McNemar test: P = .008, odds ratio: 3.36 [95% confidence interval: 1.44-7.86]). Patient-reported improvement was highly reliable in relation to MID-defined amelioration on any one scale. Discussion: In subjects with CIDP, MID-defined amelioration of any one of three commonly used outcome measures offers optimum relevance and sensitivity to detect self-identifying treatment-responders. Patient reliability to single-question ascertainment of response is high in relation to MID-defined clinical relevance. These findings support use of multiple outcome measures in CIDP monitoring and justify enhanced patient involvement in the process.en_US
dc.language.isoenen_US
dc.publisherJohn Wiley & Sonsen_US
dc.relation.urlhttp://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4598en_US
dc.rights© 2021 Wiley Periodicals LLC.
dc.subjectNeurologyen_US
dc.titleMinimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy.en_US
dc.typeArticleen_US
dc.source.journaltitleMuscle & Nerveen_US
dc.source.volume64
dc.source.issue1
dc.source.beginpage37
dc.source.endpage42
dc.source.countryUnited States
rioxxterms.versionNAen_US
dc.contributor.trustauthorRajabally, Yusuf A
dc.contributor.trustauthorAfzal, Saadia
dc.contributor.departmentNeurologyen_US
dc.contributor.departmentNeurophysiologyen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record